Ehrfeld Mikrotechnik BTS, a Bayer Technology Services company, to exclusively manufacture and market Lonza microreactors / Joint forces to develop green chemical syntheses

Wendelsheim, Leverkusen (Germany), Basel (Switzerland), February 19, 2010 – Ehrfeld Mikrotechnik BTS (EMB), a Bayer Technology Services company, and Lonza signed a worldwide manufacturing and distribution license agreement together with a cooperation and development agreement on the Lonza microreactor technology. Under the terms of the agreements, EMB will acquire a license from Lonza on two key products: the Lonza Development Microreactor (process development) and Lonza Advanced Production Microreactors (manufacturing). As a result, EMB will become the exclusive worldwide manufacturer, vendor, and distributor of Lonza microreactors. Lonza microreactors are the most advanced reactor technology for numerous chemical syntheses based on micro-structured devices. The technology recently won the prestigious Swiss Sandmeyer prize for industrial chemistry and the Profile in Sustainability award from Informex. Lonza and EMB also agree to further develop the product via the cooperation and development agreement.

“Both agreements are strategic for Lonza as they will broaden the base of users to freely utilize this cutting-edge reactor technology to develop the greener and sustainable processes of tomorrow”, says Dominique Roberge, Head of Microreactor Technology Business Development. “We are excited to continue to develop the Microreactor Technology and to strengthen the leading position of Lonza in this field”.

“This cooperation is an excellent strategic fit for us to extend our outstanding microreation technology portfolio with proven technology and know-how to serve our customers world wide,” says Dr. Olaf Stange, Managing Director of EMB. “Together with Lonza and our key experts at Bayer Technology Services we are looking forward to becoming the leading supplier and consultant in the field of microreaction technology.”

About Lonza

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.

About Ehrfeld Mikrotechnik BTS GmbH

Ehrfeld Mikrotechnik BTS GmbH, a subsidiary of Bayer Technology Services GmbH, is one of the worldwide leading providers of services and products in the area of microreaction technology.

About Bayer Technology Services

Bayer Technology Services GmbH offers fully integrated solutions throughout the lifecycle of chemical and pharmaceutical plants – from development, planning and construction, to the process optimization of existing plants. The Bayer subsidiary employs almost 2,600 experts worldwide at its headquarters in Leverkusen and other German sites, as well as in regional offices in Belgium, India, Mexico, Switzerland, the United States, the United Arab Emirates and China. In 2008, the company achieved sales of approximately EUR 420 million. Additional information about Ehrfeld Mikrotechnik BTS and Bayer Technology Services is available at www.ehrfeld.com and www.bayertechnology.com.

Find more information at www.bayertechnology.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.